Atypical antipsychotics in the treatment of schizophrenia

Swiss Medical Weekly

Volumn 133, Issue 5-6, 2003, Pages 63-76

  Bridler, René ^a,b   Umbricht, Daniel ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b Ambulantes Zentrum Ost   (Switzerland)

Author keywords

Atypical antipsychotics; Schizophrenia; Side effects; Treatment

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CAFFEINE; CARBAMAZEPINE; CIGARETTE SMOKE; CIMETIDINE; CIPROFLOXACIN; CLOZAPINE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; LEVOMEPROMAZINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENYTOIN; QUETIAPINE; RANITIDINE; RIFAMPICIN; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANTICHOLINERGIC EFFECT; ATAXIA; CIGARETTE SMOKING; CONSTIPATION; DELIRIUM; DISORIENTATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DYSARTHRIA; DYSPNEA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERICUM; HYPERPROLACTINEMIA; HYPERSALIVATION; LONG QT SYNDROME; LONG TERM CARE; MICTURITION DISORDER; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; THORAX PAIN; VISUAL DISORDER; WEIGHT GAIN;

EID: 0037425717     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87.
2. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 1986;47 Suppl:30-33.
3. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry 1998;155:565-7.
4. Quraishi S, David A. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev 2000;CD001361.
5. Quraishi S, David A. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Database Syst Rev 2000;CD001470.
6. Kane JM, Aguglia E, Altamura AC, Ayuso GJ, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66.
7. Kane JM. Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry 1999;174(Suppl 37):26-9.
8. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs? Br J Psychiatry 1981;138:490-4.
9. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509-18.
10. Kane JM. Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry 1983;44:3-6.
11. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
12. Angermeyer MC, Held T, Gortler D. Pro and contra: psychotherapy and psychopharmacotherapy attitude of the public. Psychother Psychosom Med Psychol 1993;43:286-92.
13. Seemann U, Kissling W. Prevention of relapse in schizophrenia is discontinued too soon. Many colleagues make this mistake!. MMW Fortschr Med 2000;142::34-8.
14. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000;157:1019-20.
15. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry 1993;22(Suppl):7-18.
16. Klimke A, Klieser E. The atypical neuroleptic clozapine (Leponex) - current knowledge and recent clinical aspects. Fortschr Neurol Psychiatr 1995;63:173-93.
17. Kane JM, Honigfeld G, Singer J, Meltzer HY, Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-896.
18. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3: 1607-19.
19. Chiodo LA, Bunney BS. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 1985;5:2539-44.
20. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
21. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155:921-8.
22. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Molecular Psychiatry 1998;3:135-40.
23. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-9.
24. Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc' HC, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 1996;124:154-8.
25. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15:19S-23S.
26. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacol 1997;16:1-7.
27. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869-75.
28. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, et al. The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry 2002; 15(Suppl 1):S1-S51.
29. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156:990-9.
30. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
31. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-90.
32. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
33. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 1999;60(Suppl 11):1-80.
34. Carpenter WT Jr., Arango C, Buchanan RW, Kirkpatrick B. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry 1999;46:352-60.
35. Carpenter WT Jr., Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-83.
36. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86.
37. Whiteford HA, Peabody CA. The differential diagnosis of negative symptoms in chronic schizophrenia. Aust N Z J Psychiatry 1989;23:491-6.
38. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-9.
39. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154:466-74.
40. Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am J Psychiatry 1999;156:88-93.
41. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157: 987-93.
42. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999;156: 610-6.
43. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997; 170:18-22.
44. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72.
45. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995;152:130-3.
46. Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997; 171:564-8.
47. Schmidt AW, Lebel LA, Howard HR Jr., Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.
48. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998;18:208-11.
49. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17:207-15.
50. Olie JP, Spina E, Benattia I. Ziprasidone vs amisulpride for negative symptoms. Eur Psychiatry 2002;17(Suppl 1):103.
51. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-23.
52. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
53. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry, 2001;58:965-72.
54. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;CD000059.
55. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153:1579-84.
56. Cooper TB. Clozapine plasma level monitoring: current status. Psychiatric Quarterly 1996;67:297-311.
57. Rao ML, Hiemke C, Grasmader K, Baumann P. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 2001;69:510-7.
58. Smith RC, Chua JW, Lipetsker B, Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996;57:460-66.
59. Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry 1997;58:479-83.
60. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499-504.
61. Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 1999;44:701-4.
62. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-11.
63. Wirshing DA, Marshall BD Jr., Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-9.
64. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155: 914-20.
65. Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 1999;46:73-7.
66. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-31.
67. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
68. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bulletin 1992;18:437-47.
69. Willson DF, Bilder RM, Reiter G, Barr WB, Lieberman JA. Memory deficits in first episode schizophrenia: beyond impaired acquisition. Biol Psychiatry 1995;37:593-683.
70. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-31.
71. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997; 42:255-64.
72. Bilder RM. The neuropsychology of schizophrenia: What, when, where, how? in Schizophrene Störungen: State of the Art II, Ursachen - Behandlung - Verlauf. Edited by Fleischhacker WW, Hinterhuber H, Meise U. Innsbruck, Verlag Integrative Psychiatrie; 1998.
73. Pantelis C, Nelson HE, Barnes TRE. Schizophrenia: A Neuropsychological Perspective. 1st ed. New York, John Wiley & Sons, 1998.
74. Goldman RS, Axelrod BN, Taylor AE. Neuropsychological aspects of schizophrenia in Neuropsychological Assessment in Neuropsychiatric Disorders. Edited by Grant I, Adams KM. New York, Oxford University Press; 1996.
75. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bulletin 1994; 20:31-46.
76. Pritchard WS. Cognitive event-related potential correlates of schizophrenia. Psychol Bull 1986;100:43-66.
77. Pfefferbaum A, Wenegrat BG, Ford JM, Roth WT, Kopell BS. Clinical application of the P3 component of event-relayed potentials. II dementia, depression and schizophrenia. Electroencephalogr Clin Neurophysiol 1984;59:104-24.
78. Javitt DC, Doneshka P, Grochowski S, Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 1995; 52:550-8.
79. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 1993;33:513-9.
80. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Arch Gen Psychiatry 1990;47:181-8.
81. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992;49:206-15.
82. Goldman RS, Axelrod BN, Tandon R, Ribeiro SC, Craig K, Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993;26:122-6.
83. King DJ, Green JF. Medication and cognitive functioning in schizophrenia in Schizophrenia: A Neuropsychological Perspective. Edited by Pantelis C, Nelson HE, Barnes TRE, New York, John Wiley & Sons; 1998.
84. Cornblatt BA, Keilp JG. Impaired attention: a trait indicator of the schizophrenia genotype and contributor to the clinical phenotype. Schizophr Bulletin; 1994.
85. McGurk S, Meltzer H. The effects of atypical antipsychotic drugs on cognitive functioning in schizophrenia. Schizophr Res 1998;29:160.
86. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bulletin 1999;25:233-55.
87. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-84.
88. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-8.
89. Green MF, Marshall BD Jr., Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
90. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
91. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000; 57:249-58.
92. Siris SG. Depression and Schizophrenia in Schizophrenia. Edited by Hirsch SR, Weinberger DR. Oxford, England, Blackwell Sience; 1995.
93. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry 1993;150:1643-8.
94. Keck PE Jr., Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000;61(Suppl 3):4-9.
95. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90.
96. Young F, Meltzer H, Alphs L, Anand R, Green A, Potkin S, et al. The Intersept Study: Reduced suicidal behavior in schizophrenic clozapine-treated patients. Int J Neuropsychopharmacol 2002;5(Suppl 1):S77.
97. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-9.
98. Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brucke T, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacol 1997;133:323-8.
99. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacol 1998;135: 119-26.
100. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:L103-L107.
101. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-9.
102. Jauss M, Schroder J, Pantel J, Bachmann S, Gerdsen I, Mundt C. Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry 1998;31:146-8.
103. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999;35(Suppl):S61-S66.
104. Umbricht DSG, Kane JM. Understanding the Relationship between Extrapyramidal Side Effects and Tardive Dyskinesia in Serotonin in Antipsychotic Treatment. Edited by Kane JM, Möller H-J, Awouters F. New York, Marcel Dekker, Inc., 1996.
105. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-81.
106. Saltz BL, Kane JM, Woerner MG, Lieberman JA, Alvir JM, Blank K, et al. Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 1989;25:52-6.
107. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-6.
108. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacol Suppl 1985;2:72-8.
109. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
110. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984;20: 387-9.
111. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-5.
112. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
113. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000;1:783-801.
114. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22.
115. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-30.
116. Larach VW, Zamboni RT, Mancini HR, Mancini RR, Gallardo RT. New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr Res 1997;28:231-46.
117. Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 1989;25:57-62.
118. Modestin J, Stephan PL, Erni T, Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000;42:223-30.
119. Brady CT. Weight gain associated with psychotropic drugs. South Med J 1989;82:611-6.
120. Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry 2000;61(Suppl 8):36-41.
121. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100:3-16.
122. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-96.
123. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24:59-73.
124. Brecher M, Rak IW, Melvin K, Jones AM. The long-term effect of quetiapine (Seroquel TM) monotherapy on weight in patients with schizophrenia. Intern J Psychiatry in Clin Practice 2000;4:287-91.
125. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 2001;62(Suppl 27):27-34.
126. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-81.
127. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-45.
128. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
129. Mir S, Taylor D. Atypical antipsychotics and hyperglycemia. Int Clin Psychopharmacol 2001;16:63-73.
130. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999;60:556-7.
131. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000; 41:369-70.
132. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35(Suppl):S67-S73.
133. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35(Suppl):S75-S86.
134. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295-305.
135. Shiwach RS, Carmody TJ. Prolactogenic effects of risperidone in male patients - a preliminary study. Acta Psychiatr Scand 1998;98:81-3.
136. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res 1999;92:33-44.
137. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002; 3:1381-91.
138. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;28:5-16.
139. Steinwachs A, Grohmann R, Pedrosa F, Ruther E, Schwerdtner I. Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry 1999;32:154-6.
140. Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis. Lancet 1999;354:566-7.
141. Schuld A, Kraus T, Hinze-Selch D, Haack M, Pollmacher T. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia. Acta Psychiatr Scand 2000;102:153-5.
142. Flynn SW, Altman S, MacEwan GW, Black LL, Greenidge LL, Honer WG. Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J Clin Psychopharmacol 1997;17:494-5.
143. Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999;354:567.
144. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002; 159:1435.
145. Bridler R, Hell D. Acute life threatening catatonia - clinical significance and therapeutic possibilities. Schweiz Med Wochenschr 1997;127:1531-8.
146. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21:382-8.
147. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
148. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585-9.
149. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996;156:675-7.
150. Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991;52:21-2.
151. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996;6:69-71.
152. Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, et al. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 2001;23:228-31.
153. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002;17:141-3.
154. Takahashi H, Yoshida K, Higuchi H, Shimizu T. Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports. Clin Neuropharmacol 2001;24:358-60.
155. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002;22:121-30.
156. Yagdiran O, Haasen C, Nika E, Krausz M, Naber D. Switching to amisulpride due to hepatic complications. Eur Psychiatry 2002;17:170-1.
157. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000;49(Suppl 1):71S-76S.
158. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000;49(Suppl 1):65S-70S.
159. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321: 1371-6.
160. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999;52:782-5.
161. Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry Suppl 1998;172: 66-70.
162. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-9.
163. Tenyi T, Csabi G, Trixler M. Antipsychotics and breast-feeding: a review of the literature. Paediatr Drugs 2000;2:23-8.
164. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47: 1382-4.
165. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998;59:585-8.
166. Shore D. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bulletin 1995;21: 333-8.
167. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 2001;155:230-3.